T1	intervention 53 64	fulvestrant
T2	control 79 89	exemestane
T4	outcome-Measure 886 911	time to progression (TTP)
T5	total-participants 1120 1123	693
T6	intervention-participants 1173 1176	351
T7	control-participants 1197 1200	342
T8	outcome 1286 1296	Median TTP
T9	iv-cont-median 1301 1311	3.7 months
T12	outcome 1390 1411	overall response rate
T13	iv-bin-percent 1413 1417	7.4%
T14	cv-bin-percent 1420 1424	6.7%
T15	outcome 1440 1461	clinical benefit rate
T16	iv-bin-percent 1463 1468	32.2%
T17	cv-bin-percent 1471 1476	31.5%
T19	iv-cont-median 1590 1593	9.3
T20	cv-cont-median 1598 1608	8.3 months
T21	outcome 1700 1746	incidence of adverse events or quality of life
T3	outcome 1550 1585	Median duration of clinical benefit
T10	outcome 1645 1659	well tolerated
